AstraZeneca completes acquisition of Pearl Therapeutics
28th Jun 2013 07:02
FTSE 100-listed biopharmaceutical business AstraZeneca has completed the acquisition of Pearl Therapeutics, a California-based company focused on the development of inhaled small-molecule therapeutics for respiratory disease. Upon completion of the merger, AstraZeneca acquired 100% of Pearl's shar
Read moreLondon pre-open: Tentative start expected as markets wait for Fed meeting
19th Jun 2013 07:25
Stocks are expected to open with only small gains on Wednesday morning as nervous investors refrain from building positions ahead of the Federal Reserve policy announcement after the market-close this evening. City sources predict the FTSE 100 will open up just eight points from yesterday's close o
Read moreAstraZeneca announces results of SAVOR study
19th Jun 2013 07:02
AstraZeneca has completed the fourth phase of its clinical trial of diabetes treatment Onglyza. Data from the SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial is being analysed and will be submitted to the European Society of Car
Read moreAstraZeneca sets up new headquarters in Cambridge
18th Jun 2013 13:07
Pharmaceutical company AstraZeneca is launching its global headquarters at the Cambridge Biomedical Campus. The research and development(R&D) site, which is expected to be open by 2016, is a £330m project. It will replace R&D at Alderley Park in Cheshire which will cease operations. The company
Read moreTuesday tips round-up: Xaar, AstraZeneca, Gemfields
11th Jun 2013 07:17
Since having floated itself back in 1996 at about a quid, inkjet printing technology outfit Xaar has metamorphosed into the market leader for the digital technology used to produce ceramic tiles ? a huge market, especially in China. About 15 per cent of tiles are produced digitally at present, but t
Read moreBroker tips: Lloyds, AstraZeneca, Betfair
10th Jun 2013 10:48
Investec has retained its 'sell' rating and 50p target price for part-nationalised lender Lloyds as speculation continues to increase ahead of a potential reprivatisation. The broker said it sees "little justification for the share price to react favourably" under the proposal from the Policy Excha
Read moreBroker snap: Pamure hails AstraZeneca's latest purchase
10th Jun 2013 10:32
Panmure Gordon has retained its 'hold' rating and 3,200p target price for biopharmaceutical group AstraZeneca, but celebrated the company's 560m-dollar acquisition of Pearl Therapeutics on Monday, a necessary move in the broker's opinion. The firm announced that it has entered into an agreement to
Read moreAstraZeneca to acquire Pearl Therapeutics to strengthen drug pipeline
10th Jun 2013 07:14
FTSE 100-listed global pharmaceuticals group AstraZeneca has entered into a definitive agreement to acquire Redwood City-based Pearl Therapeutics, an update issued by the group has shown. Pearl Therapeutics is a privately held company focused on the development of inhaled small-molecule therapeuti
Read moreFriday broker round-up UPDATE
7th Jun 2013 06:51
Aberdeeen Asset Management: Bank of America cuts target price from 475p to 410p downgrading to underperform. Anglo American: Nomura lowers target price from 1700p to 1650p and stays with its neutral rating. ARM Holdings: UBS moves target price from 950p to 970p, while its neutral rating remains un
Read moreThursday tips round-up: John Wood, RPC, Astra Zeneca
6th Jun 2013 10:24
The oil exploration sector has been battered by profit warnings and a perceived lack of orders in some territories, but John Wood Group is strong in deepwater engineering and in developed economies, while contracts tend to be on a less risky re-imbursable basis. In brief, that is the jist of a recen
Read moreLondon close: Stocks rise as Fed speculation continues
4th Jun 2013 16:55
Speculation surrounding the future of the Federal Reserve's stimulus programme continued to drive market sentiment on Tuesday as stocks rebounded on hopes that the US central bank will delay scaling back measures as it awaits a firmer recovery. The FTSE 100 rose 33 points (+0.51%) to 6,559 today af
Read moreLondon midday: Stocks gain on US stimulus hopes, UK construction data
4th Jun 2013 11:45
Hopes that the US Federal Reserve would delay pulling the plug on stimulus and a surprise return to growth in the UK construction sector gave markets a boost on Tuesday morning, with the FTSE 100 rebounding from a one-month low the day before. London's FTSE 100 fell to 6,525 on Monday, a level not
Read moreBroker tips: AstraZeneca, Serco, GKN
4th Jun 2013 11:03
Panmure Gordon has retained its 'hold' rating and 3,200p target price for biopharmaceuticals group AstraZeneca, saying that the news of the pull-out from fostamatinib should remind investors of the risks that the business carries. "Today's news of another phase III product opportunity slipping away
Read moreBroker snap: AstraZeneca needs to start delivering, says Panmure
4th Jun 2013 10:24
Panmure Gordon has retained its 'hold' rating and 3,200p target price for biopharmaceuticals group AstraZeneca, saying that the news of the pull-out from fostamatinib should remind investors of the risks that the business carries. Astra announced on Tuesday that it has decided not to pursue regulat
Read moreLondon open: Markets rebound as 'tapering' concerns ease
4th Jun 2013 09:10
Markets rebounded on Tuesday morning following a choppy session the day before as renewed hopes about US stimulus lifted sentiment early on. London's FTSE 100 lost 58 points yesterday, falling 0.9% to a one-month low of 6,525, after factory activity in both China and the US weakened in May. Manufac
Read more